Researchers at Georgetown University have developed a new drug called CTPI-2, which targets a key gene known as Slc25a1. This ...

Altimmune's pemvidutide shows promise in treating MASH and obesity, with upcoming Phase 2b results poised to shape its market impact. Read more on ALT stock here.

The promise of big rewards for a successful drug treatment of NASH has spurred dozens of drug developers to try to develop the first therapy for the fatty liver disease, which affects millions of ...